Startups
MapLight Therapeutics
MapLight Therapeutics is a clinical-stage neuroscience biotechnology company developing medicines for central nervous system disorders. Its discovery approach combines neural-circuit mapping, optogenetics and molecular profiling to identify disease-related circuits and targets for drug development. Programs include the investigational muscarinic-receptor combination ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis and ML-004 for autism-related symptoms. Christopher Kroeger leads the company; scientific founders include Karl Deisseroth and Robert Malenka. Its public roster includes management, directors, scientific advisers and clinical advisers. MapLight began Nasdaq trading under MPLT on October 27, 2025. Financing includes a USD225 million Series C, a Series D with USD200 million actually raised against a larger announced commitment, an IPO with approximately USD288.36 million gross proceeds, a separate concurrent private placement of approximately USD8.10 million and a USD150 million PIPE announced in August 2026. Its programs remain investigational.
Team
 Anatol KreitzerChief Discovery Officer |
 Anissa Abi-DarghamClinical Advisory Board Member |
 Anton P. PorsteinssonClinical Advisory Board Member |
 Bernard SilvermanClinical Advisory Board Member |
 Christopher KroegerChief Executive Officer · Founder · Board Director |
 Erin Pennock FoffChief Medical Officer |
 George PavlovBoard Director |
 Hongkui ZengScientific Advisory Board Member |
 Ivan SolteszScientific Advisory Board Member |
 James LillieChief Scientific Officer |
 John KaneClinical Advisory Board Member |
 Jonathan GillisInterim Chief Financial Officer, Chief Administrative and Accounting Officer |
 Judith JaegerClinical Advisory Board Member |
 Karl DeisserothFounder · Scientific Advisory Board Member |
 Karoly NikolichAdvisory Board Member |
 Kris HansonGeneral Counsel |
 Maria WalkerBoard Director |
 Martin BablerBoard Director |
 Matthew StateScientific Advisory Board Member |
 Nanna LüneborgBoard Director |
 Pierre N. TariotClinical Advisory Board Member |
 Robert MalenkaFounder · Scientific Advisory Board Member |
 Suzanne HendrixClinical Advisory Board Member |
 Timothy GarnettBoard Director |
 Troy CoxBoard Director |
Investments
| $150M2026-08-13 | MapLight Therapeutics | Forbion, Life Sciences at Goldman Sachs Alternatives, Deep Track Capital, Avego BioScience Capital |
| $8M2025-10-26 | MapLight Therapeutics | 0 participations |
| $288M2025-10-26 | MapLight Therapeutics | 0 participations |
| $200M2025-07-28 | MapLight Therapeutics | Forbion, Life Sciences at Goldman Sachs Alternatives, Novo Holdings, 5am Ventures, Blue Owl Healthcare Opportunities, Pivotal bioVenture Partners, Avego BioScience Capital |
| $225M2023-10-30 | MapLight Therapeutics | Novo Holdings, 5am Ventures, Cowen Healthcare Investments, Pivotal bioVenture Partners, Christopher Kroeger |
| $—Unknown date |  Stellaromics | MapLight Therapeutics |
| $12MUnknown date | MapLight Therapeutics | 0 participations |
| $53MUnknown date | MapLight Therapeutics | 0 participations |
| $16MUnknown date | MapLight Therapeutics | 0 participations |
| $5MUnknown date | MapLight Therapeutics | 0 participations |